Structure Therapeutics Inc. (NASDAQ:GPCR) Given Average Recommendation of "Buy" by Brokerages

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) have been assigned an average recommendation of "Buy" from the eight analysts that are presently covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $81.29.

Several equities analysts have recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a research report on Tuesday. William Blair initiated coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 target price for the company.

Structure Therapeutics Price Performance

NASDAQ GPCR traded down $0.40 on Friday, hitting $22.92. The company had a trading volume of 339,975 shares, compared to its average volume of 926,340. The company's fifty day moving average price is $20.16 and its 200-day moving average price is $28.10. The company has a market capitalization of $1.31 billion, a PE ratio of -30.97 and a beta of -1.35. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. On average, sell-side analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GPCR. Geode Capital Management LLC increased its position in Structure Therapeutics by 0.7% during the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock worth $1,985,000 after purchasing an additional 312 shares during the last quarter. Virtus ETF Advisers LLC grew its stake in shares of Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after buying an additional 455 shares during the period. ANTIPODES PARTNERS Ltd increased its holdings in shares of Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after buying an additional 553 shares during the last quarter. LPL Financial LLC raised its position in shares of Structure Therapeutics by 6.0% during the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after buying an additional 646 shares during the period. Finally, Envestnet Asset Management Inc. lifted its holdings in Structure Therapeutics by 12.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock valued at $201,000 after acquiring an additional 843 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.